Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
Status:
Completed
Trial end date:
2019-08-05
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled,
randomized, single-ascending dose, multi-center study to assess the safety, efficacy,
tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in participants
with acute submassive pulmonary embolism.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc.
Collaborators:
International Trial Expertise and Advisory Servies (ITREAS) Medpace, Inc.